Practical Pearls for Diagnosing Disorders of Hyperpigmentation
If you find diagnosing disorders of hyperpigmentation challenging, then this is just for you! I had the privilege of attending the 2023 ODAC Dermatology, Aesthetic, and Surgical Conference to learn about disorders of hyperpigmentation from Dr. Nada Elbuluk. Dr. Elbuluk is an Associate Professor and Director of the Skin of Color Program and Pigmentary Disorders Clinic at the University of Southern …
If you find diagnosing disorders of hyperpigmentation challenging, then this is just for you! I had the privilege of attending the 2023 ODAC Dermatology, Aesthetic, and Surgical Conference to learn about disorders of hyperpigmentation from Dr. Nada Elbuluk. Dr. Elbuluk is an Associate Professor and Director of the Skin of Color Program and Pigmentary Disorders Clinic at the University of Southern … Continue reading "Practical Pearls for Diagnosing Disorders of Hyperpigmentation"
INTRODUCTION
Linear lichen planus pigmentosus (LPP) of the face is a rare acquired variant of lichen planus, with only a few cases published in the literature.1 It is an inflammatory condition with unknown etiology, characterized by blue-gray hyperpigmented macules, and tends to affect sun-exposed areas of the head and neck.1-4 The pathophysiology of linear LPP is poorly understood, though … 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. George Han (Vice President of the Dermatologic Society of Greater New York, member of the board of directors of the New York State Society of Dermatology and Dermatologic Surgery, and member of the Medical Board of the National Psoriasis Foundation), who offers tips on better directing pa … 
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …